“I’ll see your neoepitope and raise you a tumor-infiltrating lymphocyte.” Such bets could be placed more confidently if cancer immunotherapy would deal itself a stronger hand, one that would include the “juiciest” T cells—the T cells that are best at recognizing and killing cancer cells. Unfortunately, the juiciest T cells often get lost in the shuffle. Either they don’t reach the bloodstream, where many T cells intended for cell-based immunotherapy are drawn, or they end up at the bottom of the tumor-infiltrating lymphocyte (TIL) deck. Not content to play the hand they were dealt, scientists at the Ludwig Institute for Cancer Research decided that a little bottom dealing might be in order. “We developed a new methodology to identify highly reactive TILs and expand them in a manner that, rather than diluting the juiciest TILs, enriches them instead," said Alexandre Harari, a Ludwig Lausanne investigator and a ...
Original Article: Immunotherapy Raises the Stakes and Ovarian Cancer Blinks
NEXT ARTICLE